Pharmaceuticals
Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
-- Gannex is expected to release topline data of the Phase II clinical trial by the end of 2023 SHANGHAI, July 20, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today the completion of enrollment of 98 patients with ...
2023-07-20 08:10
3330
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise stated[...
2023-07-19 16:14
3155
The International Conference on Pharmaceutical Innovation and Development 2023 Kicked off in Yantai
YANTAI, China, July 19, 2023 /PRNewswire/ -- On the morning of July 13, the International Conference on Pharmaceutical Innovation and Development 2023 kicked off in Yantai. The conference was hosted by the People's Government of Shandong Province, co-sponsored by the Chinese Pharmaceutical Associa...
2023-07-19 16:09
2637
Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet
SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo Tab., the 1st SGLT-2 inhibitor by Korea, expanding its product portfolio. Daewoong Pharmaceutical (Jeon Sen...
2023-07-19 08:52
2927
First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib
MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstad...
2023-07-19 05:00
2931
Join Taipei City's Thriving Health Industry: Registration for "Win A Greater Health" Pitch Contest Starts Now!
TAIPEI, July 18, 2023 /PRNewswire/ -- The Taipei City Government's Department of Economic Development is taking proactive steps to attract international startups and foster collaboration with local businesses through its "Talent Exchange Program". In line with this initiative, they have establish...
2023-07-18 11:35
2732
Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States
- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop, commercialize, and manufacture ATG-017 - The combination portion of the ERASER study, the first-in-human (FIH) study of ATG-017, was designed to evaluate the safety/tole...
2023-07-18 08:30
2725
ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023
AMSTERDAM, July 17, 2023 /PRNewswire/ -- The data reported today by Eli Lilly from theTRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer's disease demonstrate an important advancement in Alzheimer's research and treatment. The full Phase 3 data was reported at the Alzh...
2023-07-17 21:15
2958
Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma
* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has received regulatory approvals in 41 countries and regions includingthe United States, Israel, the United Kingdom, the European Union (the 27 member countries includingFrance and Italy), Canada, Norw...
2023-07-17 08:30
3247
Red Marrow Peptide-A Major Breakthrough in Human Health Engineering
BEIJING, July 14, 2023 /PRNewswire/ -- 1.8 g! This figure refers to the weight of red marrow which can be extracted from a 100 kg young yak growing in no-human zone ofQinghai and enjoys the reputation of "the key of cardiovascular health". It is called the most perfect "blood scavenger", ...
2023-07-14 12:51
2600
Menarini Silicon Biosystems announces the launch of its new CELLSEARCH® CTC test with the DLL3 biomarker for small cell lung cancer
This new CELLSEARCH Circulating Tumor Cell (CTC) test is now available as a Research Use Only (RUO) lab service inNorth America and Europe. It is currently intended for basic and pharmaceutical research and it is the latest example of how Menarini Silicon Biosystems continues its development of c...
2023-07-13 20:00
3725
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby...
2023-07-12 20:45
3408
Raya Therapeutic announces early-stage R&D collaboration with argenx
MONTREAL, July 12, 2023 /PRNewswire/ -- Raya Therapeutic Inc., ("Raya") a mission-driven company focused on the treatment of neurodegenerative diseases, has entered into an early-stage R&D collaboration with argenx. The collaboration focuses on testing combinations of Raya's pipeline of targeted ...
2023-07-12 19:07
2506
Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation
SINGAPORE, July 12, 2023 /PRNewswire/ -- On July 6, 2023, Biosyngen received an official notification from the U.S. Food and Drug Administration (FDA) granting Fast Track Designation (FTD) to its revolutionary first-in-class immunotherapy, BRG01, for the treatment of relapsed/metastatic nasophary...
2023-07-12 13:38
4020
Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.
SINGAPORE, July 12, 2023 /PRNewswire/ -- This is a model of cooperation between Singapore and China, more importantly, working jointly in the area of research and development. Through this initiative, China Singapore Knowledge City paths the way to attract both local and overseas therapeutic asse...
2023-07-12 10:32
3655
Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism
HANGZHOU, China and SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characteriza...
2023-07-12 10:00
3310
GI Dynamics Announces Company Rebrand as Morphic Medical® Reintroducing Flagship Product as RESET®
BOSTON, July 11, 2023 /PRNewswire/ -- GI Dynamics, creator of the world's first medical device designed to target the underlying cause of type 2 diabetes, is proud to announce its rebrand to Morphic Medical and the introduction of RESET, formally known as EndoBarrier®. This transformative shift r...
2023-07-12 07:12
2588
Race executes global license agreement with City of Hope to access FTO IP
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...
2023-07-11 07:30
3219
Rx-360 Expands Trademark Portfolio to Japan
PHILADELPHIA, July 10, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium has now expanded their trademark registration for Joint Audit Program® logo to now include Japan. Through the achievement of this milestone, Rx-360 has secured trademark registration for Rx360 and the J...
2023-07-10 18:00
2220
Calling Bright Minds in Southeast Asia, Bio Farma and MIT Hacking Medicine is Set to Revolutionize Healthcare with a 4-Day Hackathon
JAKARTA, Indonesia, July 10, 2023 /PRNewswire/ -- Bio Farma
2023-07-10 15:19
3451
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 319 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 316 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Tower Capital Asia announces majority investment in V-Key - a leader in digital identity and mobile application security
[Picked up by 265 media titles]
2026-02-13 01:52
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Most Read
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
8093
Cboe Launches Nearly 24-Hour Trading in Russell 2000 Index Options
2026-02-13 07:30
7371
Appier Delivers Record Results Driven by Agentic AI Innovation
2026-02-13 17:03
6861